Douglass Winthrop Advisors LLC Purchases New Shares in Solventum Co. (NYSE:SOLV)

Douglass Winthrop Advisors LLC purchased a new position in shares of Solventum Co. (NYSE:SOLV) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 3,579 shares of the company’s stock, valued at approximately $250,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD bought a new stake in shares of Solventum during the first quarter valued at approximately $5,889,000. CWM LLC acquired a new stake in shares of Solventum in the 2nd quarter valued at $473,000. Great Valley Advisor Group Inc. bought a new stake in shares of Solventum during the second quarter worth $493,000. First Horizon Advisors Inc. acquired a new position in shares of Solventum during the second quarter valued at $58,000. Finally, Swedbank AB bought a new position in Solventum in the second quarter valued at about $4,711,000.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SOLV. BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating for the company. Stifel Nicolaus assumed coverage on shares of Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target for the company. Morgan Stanley raised their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. The Goldman Sachs Group upped their target price on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday, August 12th. Finally, Wells Fargo & Company decreased their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $68.00.

Solventum Price Performance

Shares of NYSE SOLV opened at $71.58 on Tuesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company’s fifty day moving average is $70.52 and its 200-day moving average is $62.35.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.